Pfizer Inc. $PFE Shares Purchased by Andra AP fonden

Key Points

• Andra AP fonden increased its Pfizer stake by 196.6% in the second quarter, acquiring 482,700 additional shares for a total of 728,273 shares valued at approximately $17.5 million. Institutional investors collectively own 68.36% of Pfizer.
• Pfizer shares were trading at $27.92, near the upper end of their 12-month range. The company exceeded quarterly earnings and revenue expectations, reporting $0.77 in EPS and $15.03 billion in revenue, while guiding for fiscal 2026 EPS of $2.80–$3.00.
• Analyst sentiment remains cautious, with an average “Hold” rating and an average price target of $28.39. Investors remain focused on Pfizer’s patent expirations, declining COVID-19 revenue, pricing pressures and the company’s ability to develop replacement products.

Andra AP fonden raised its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 196.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 728,273 shares of the biopharmaceutical company's stock after acquiring an additional 482,700 shares during the quarter. Andra AP fonden's holdings in Pfizer were worth $17,537,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in PFE. State Street Corp grew its position in shares of Pfizer by 1.8% in the second quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company's stock valued at $7,394,749,000 after purchasing an additional 5,501,032 shares during the last quarter. Security National Bank of Sioux City Iowa IA purchased a new position in Pfizer during the second quarter worth $76,000. Bullseye Investment Management LLC purchased a new position in Pfizer during the second quarter worth $28,000. U S Wealth Group LLC. raised its holdings in shares of Pfizer by 13.1% in the second quarter. U S Wealth Group LLC. now owns 116,761 shares of the biopharmaceutical company's stock worth $2,812,000 after acquiring an additional 13,516 shares during the last quarter. Finally, Core Capital Management & Research inc. acquired a new position in shares of Pfizer in the second quarter worth $4,687,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Trading Up 0.6%

NYSE PFE opened at $27.92 on Wednesday. Pfizer Inc. has a 12 month low of $23.58 and a 12 month high of $29.21. The company has a 50-day moving average of $26.84 and a 200-day moving average of $26.39. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The company has a market cap of $159.12 billion, a P/E ratio of 36.73, a P/E/G ratio of 1.86 and a beta of 0.34.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business had revenue of $15.03 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same period last year, the company earned $0.78 earnings per share. The company's quarterly revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.98 earnings per share for the current year.

Wall Street Analyst Weigh In

PFE has been the topic of a number of analyst reports. HSBC increased their price objective on Pfizer from $28.00 to $30.00 and gave the company a "hold" rating in a research note on Thursday, September 10th. Royal Bank Of Canada raised shares of Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 price target on the stock in a research note on Tuesday, June 9th. BMO Capital Markets lowered their price target on shares of Pfizer from $34.00 to $30.00 and set an "outperform" rating for the company in a report on Monday, July 13th. UBS Group reissued a "neutral" rating and issued a $27.00 price objective on shares of Pfizer in a research report on Wednesday, May 27th. Finally, Guggenheim reduced their price objective on shares of Pfizer from $35.00 to $31.00 and set a "buy" rating on the stock in a research note on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $28.39.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Investor sentiment improved after management indicated that major headwinds—including tariffs, drug-pricing pressure, declining COVID-19 revenue and upcoming patent expirations—are beginning to ease. Pfizer’s cost-reduction efforts and newer therapies could help stabilize growth. The company’s agreement to share some incremental overseas pricing revenue with the U.S. Department of Health and Human Services may also reduce policy uncertainty. How Investors Are Reacting To Pfizer Easing Policy Pressures
• Positive Sentiment: Pfizer completed a key Phase 1 study for PF-07799544, providing a pipeline milestone. Although the program remains early stage and is not an immediate earnings driver, progress could support longer-term expectations for replacement products. Pfizer Advances PF-07799544
• Positive Sentiment: Several investor analyses argue that Pfizer’s relatively low valuation and dividend yield provide downside support and leave room for a potential re-rating once post-patent-expiration performance becomes clearer. Pfizer U.S. All Stars Conference Transcript
• Neutral Sentiment: Pfizer invited investors to a November 3 conference call with analysts. The webcast is a routine communications event, but investors will look for updated guidance and commentary on the pipeline, pricing and patent losses. Pfizer November 3 Conference Call
• Neutral Sentiment: CEO Albert Bourla’s planned attendance at a White House state dinner with China’s President Xi may support visibility for Pfizer, but it has no clear near-term earnings impact. Pfizer CEO Plans State Dinner Attendance
• Negative Sentiment: Analysts remain concerned that Pfizer’s dividend is high but largely stagnant, with future appreciation dependent on successful execution after major products lose exclusivity. One commentary downgraded the stock to Hold, arguing investors may not pay for longer-term 2029 earnings until visibility improves. Pfizer Downgraded to Hold
• Negative Sentiment: Dividend-focused comparisons with Eli Lilly and AbbVie highlight Pfizer’s weaker growth profile and greater uncertainty around future earnings, limiting enthusiasm among investors seeking both income and capital appreciation. Pfizer Versus Eli Lilly for Dividend Investors

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its portfolio addresses a range of therapeutic areas, including oncology, inflammation and immunology, internal medicine, hospital care, rare diseases and infectious diseases. The company serves patients and healthcare providers in markets worldwide.

Pfizer's products include the Comirnaty COVID-19 vaccine, the Prevnar family of pneumococcal vaccines, and medicines such as Eliquis, Ibrance, Vyndaqel and Zavzaret.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.